Clinical characteristics of patients with migraine accompanied by tremor. / åå¤´ç—›ä¼´å‘éœ‡é¢¤æ‚£è€ çš„ä¸´åºŠç‰¹å¾.

OBJECTIVES: Migraine and tremor share some genetic mutation sites, and clinical studies have also confirmed their correlation. This study aims to explore the clinical and electrophysiological characteristics of migraine patients with concomitant tremor, and to analyze the relevant influential factors of tremor occurrence. METHODS: We retrospectively analyzed the clinical data of 217 migraine patients who visited the Third Affiliated Hospital of Qiqihar Medical University from June 2022 to October 2023. The Clinical Rating Scale for Tremor (CRST), Numerical Rating Scale (NRS), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9) were respectively used to assess the tremor symptoms, degree of headache, anxiety, and depression of patients. All patients underwent routine head MR scanning and electromyography examination, and were divided into a migraine with tremor group and a migraine without tremor group based on the electromyogram examination. RESULTS: The migraine with tremor group and the migraine without tremor group were included 52 patients (23.96%) and 165 patients (76.04%), respectively. Compared with the migraine without tremor group, the migraine with tremor group had a longer course and duration of headache, higher frequency of headache attacks, higher NRS score, GAD-7 score, and PHQ-9 score, and fewer weekly physical exercises. The differences were statistically significant (all P<0.05). There were no statistically significant differences in the presence or absence of prodromal headache and white matter hyperintensities (WMHs) between the 2 groups (both P>0.05). The evaluation results of the CRST showed that out of 217 migraine patients, 39 patients (17.97%) were accompanied by tremors. The electromyographic results showed that all 52 migraine patients with tremors had upper limb tremors, including 28 migraine patients with postural tremors and 24 migraine patients with static tremors. Compared with the migraine patients with static tremors, the migraine patients with postural tremors had lower average frequency, peak frequency, and headache onset frequency (all P<0.05). Multiple linear regression analysis showed that frequency of physical exercise, duration of illness, frequency of headache attacks, NRS score, GAD-7 score, and PHQ-9 score were risk factors for migraine patients with concomitant tremors (all P<0.05). CONCLUSIONS: Patients with migraine mainly experience upper limb postural tremors. Reduced physical exercise, long course of disease, long duration of headache, frequent headache attacks, severe headache, anxiety, and depression are risk factors for migraine patients with concomitant tremors.

[Cross-sectional analysis of libido status and risk factors in male patients with chronic headache].

OBJECTIVE: Exploring the libido status of male chronic headache patients and analyzing its relationship with headache symptoms, sleep, anxiety, and depression, providing reference for the comprehensive treatment of male chronic headache. METHODS: 179 patients with chronic headache who visited the Third Affiliated Hospital of Qiqihar Medical College from January 2022 to February 2023 were selected. The male Self Rated Libido Scale , Visual Analog Scale for Pain, Migraine Disability Assessment Scale, Pittsburgh Sleep Quality Index, Generalized Anxiety Disorder Scale-7, and Patient Health Questionnaire-9 were used to evaluate the libido status, headache severity, disability level, sleep quality, anxiety, and depression of the research subjects, respectively. RESULTS: Among 179 male chronic headache patients, 97 were chronic migraine (CM) patients and 82 were chronic tension type (CTT) patients, and 47 were screened for low libido. The influencing factors of libido in male chronic headache patients include age, smoking, frequency of exercise, course of disease, severity of pain, frequency of headache, disability score, sleep quality, anxiety and depression (all P<0.05). Compared with male CTT patients, male CM patients have higher pain severity, headache frequency, disability score, and anxiety score, while lower libido score (all P<0.05). The results of multivariate analysis showed that age, frequency of exercise, course of disease, severity of pain, frequency of headache, degree of disability, sleep quality, anxiety, and depression were the influencing factors for the decline of libido in male chronic headache patients. CONCLUSION: It is common for male chronic headache patients to experience decreased libido, with male chronic migraine (CM) patients exhibiting more severe reductions. Advanced age, decreased physical activity, longer disease duration, severe pain intensity, frequent headaches, higher disability levels, poor sleep, anxiety, and depression are risk factors for decreased libido in male chronic headache patients.

Comprehensive analysis of lncRNA­miRNA­mRNA regulatory networks for Alzheimer's disease.

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease, associated with a decreased cognitive function and severe behavioral abnormalities. This study aimed to explore mechanisms of development and progression of AD. Comprehensive analysis of GSE16759 was performed to identify the differentially expressed lncRNAs (DElncRNAs), miRNAs (DEmiRNAs), and mRNAs (DEmRNAs). The differentially expressed RNAs (DERs) were used for the subsequent analysis, including module genes analysis, pathway enrichment analysis, and interaction network analysis. Finally, an AD­associated network consisting of lncRNA­miRNA­mRNA­pathway was constructed. A total of 431 DEmRNAs, 35 DElncRNAs, and 103 DEmiRNAs between the AD group and the normal control group were identified. DEmRNAs were significantly enriched in 13 pathways, such as focal adhesion, endocytosis, and mTOR signaling pathway. Three modules significantly related to AD were finally screened. The AD­associated network was constructed, including 2 lncRNAs (A2M­AS1 and ZNF571­AS1), 1 miRNA (hsa­miR­206), 2 mRNAs (NOTCH3 and JAG1), and 2 pathways (notch signaling pathway and endocrine resistance). A2M­AS1, ZNF571­AS1, hsa­miR­206, NOTCH3 and JAG1 may be involved in the mechanisms of AD through notch signaling pathway and endocrine resistance.

Relationship between cobalt transporter II gene rs9606756 site mutant and serum homocysteine level and recurrent cerebral infarction in young and middle-aged people.

BACKGROUND: This study aimed to investigate the effect of cobalt transporter II gene (rs1801198, rs2301957, rs9606756) polymorphism on serum homocysteine level and its correlation with young and middle recurrent cerebral infarction. METHODS: A total of 348 young and middle-aged patients with cerebral infarction admitted to The Third Affiliated Hospital of Qiqihar Medical University from January 2017 to March 2018 were enrolled. The patients were divided into recurrent and non-recurrent groups according to follow-up. DNA was extracted from the peripheral blood of patients, and the DNA samples were genotyped by IlluminaBeadArray technology to detect the gene polymorphisms of cobalt transporter II (TCN2) sites (rs1801198, rs2301957, rs9606756), and the homocysteine (hcy) level was determined by cyclic enzymatic method. VitB12 and folate levels were measured by chemiluminescence immunoassay, and holo transcobalamin (holoTC) expression levels were detected by enzyme-linked immunosorbent assay. RESULTS: The frequency of alleles of rs9606756 mutation in the recurrent group was higher than that in the non-recurrent group (P<0.05), and the Hcy level in rs9606756 locus genotype AG+GG was significantly higher than the AA genotype in the recurrent group (P=0.031). Pearson correlation analysis showed that Hcy levels were associated with different genotypes of rs9606756 in the recurrent group (r=0.483, P=0.0003). The rs9606756 allele AA in SH-SY5Y cells was replaced with GG by point mutation experiment. The Hcy metabolism levels of wild and mutant cells were detected. The accumulation level of Hcy in the mutant group was significantly increased (P=0.007). The holoTC in the supernatant was significantly reduced in the mutant (P=0.032). CONCLUSIONS: The TCN2 gene rs9606756 mutation is closely related to the level of Hcy metabolism in young and middle-aged patients, which may affect the recurrence of cerebral infarction. It is of great significance to further understand the pathogenesis, prevention and treatment of recurrent cerebral infarction in young and middle-aged patients.

HIF-1α/microRNA-128-3p axis protects hippocampal neurons from apoptosis via the Axin1-mediated Wnt/ß-catenin signaling pathway in Parkinson's disease models.

Parkinson's disease (PD) is a progressive neurodegenerative disorder. A common and disabling disease of the elderly, the standard dopamine replacement therapies do not arrest the ongoing neurodegeneration, thus calling for new treatment strategies. The present study aimed to clarify the functional relevance of the hypoxia inducible factor-1α (HIF-1α)/microRNA-128-3p (miR-128-3p) axis in hippocampal neurodegeneration in a PD mouse model obtained by intraperitoneal injection of MPTP. Targeting relationship between miR-128-3p and Axin1 was verified, so we probed the roles of Hif1a, miR-128-3p, and Axin1 in apoptosis of hippocampal neurons with gain- and loss-of function experiments using flow cytometry and TUNEL staining. We found that Axin1 was upregulated in hippocampal tissues and cells of the MPTP-lesioned mouse model of PD, while Hif1a and miR-128-3p were downregulated. Elevation of HIF-1α/miR-128-3p inhibited apoptosis of hippocampal neurons via Wnt/ß-catenin signaling pathway activation due to the suppression of Axin1 in PD. In addition, forced overexpression of Hif1a could ameliorate motor dysfunction and pathological changes in the model. Collectively, activation of the HIF-1α/miR-128-3p axis could repress hippocampal neurodegeneration in MPTP-lesioned mice through an activated Wnt/ß-catenin pathway due to Axin1 downregulation.

Protective effect of edaravone on blood-brain barrier by affecting NRF-2/HO-1 signaling pathway.

Protective effect of edaravone on blood-brain barrier (BBB) in experimental cerebral infarction rats was investigated. SD rats were prepared as the permanent middle cerebral artery occlusion model and randomly divided into 4 groups: cerebral infarction model group, edaravone low, medium and high dose groups. Healthy rats only for operation and no filament were selected as the sham operation control group. Rats in the cerebral infarction model group and the control group were given normal saline, and those in the edaravone low, medium and high dose groups were given edaravone 10, 15 and 20 mg/kg, respectively. The survival status, the body weight and neurological function score before and after treatment, the brain water content and the permeability of the blood-brain barrier after treatment were measured. The expression levels of NFE2-related factor 2 (NRF2) and hemeoxygenase 1 (HO-1) in rat brain tissue were detected by western blotting. Levels of peripheral blood malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione (GSH) were detected by ELISA. The state of the rats in three edaravone groups was improved compared with that of the cerebral infarction group. Compared with the cerebral infarction model group, the body weight was significantly increased after treatment and the neurological function score, brain tissue water content and BBB permeability were significantly decreased in three edaravone groups (P<0.05). Compared with the model group of cerebral infarction, the expression of NRF-2 and HO-1 in the brain of the three edaravone groups was significantly higher (P<0.05). Compared with the model group of cerebral infarction, the expression of MDA and GSH in the three edaravone groups was significantly decreased, GSH and SOD was increased (P<0.05), in a dose-dependent manner. Edaravone might play a protective role in the BBB by activating the NRF-2/HO-1 signaling pathway.

Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson's disease.

Recently, it has been demonstrated that microRNA-137 (miR-137) plays a vital role in the induction of oxidative stress of neurons in Parkinson's disease (PD). Herein, the study aimed to investigate the effects of serum exosomal miR-137 on oxidative stress injury of neurons in PD. Microarray analysis was adopted to screen the PD-related differential expressed genes and predict the interaction between OXR1 and miR-137 in PD. It was found that OXR1 was down-regulated while miR-137 was up-regulated in PD. Additionally, miR-137 targeted OXR1 and negatively regulated its expression. Mouse and neuron models of PD were established to mimic the pathological changes, especially oxidative stress injury induced by PD. The significance of miR-137 and OXR1 in oxidative stress injury was investigated in neuron model of PD using gain- and loss-of-function approaches. The obtained data exhibited that inhibition of miR-137 or up-regulation of OXR1 ameliorated PD-induced oxidative stress injury, reduced pole-climbing time, but increased score for traction test as well as promoted viability and decreased apoptosis of neurons in PD model, accompanied with decreased MDA content and ROS levels, and increased SOD levels. Furthermore, PD mice were injected with serum-derived exosomes or neurons in PD models were exposed to exosomes derived from serum of PD mice. Loss-of-function experiments using miR-137 antagomir exhibited that inhibition of exosomal miR-137 ameliorated PD-induced oxidative stress injury in vitro, reduced pole-climbing time but increased score for traction test in vivo. Collectively, down-regulation of exosomal miR-137 alleviates oxidative stress injury in PD by up-regulating OXR1.